Silibinin and Nano-silibinin in Cuprizone Model of Multiple Sclerosis: Behavioral and Biochemical Investigation

被引:2
作者
Ahmadi, Yasin [1 ]
Mahboobian, Mohammad Mehdi [2 ]
Mohammadi, Mojdeh [1 ]
机构
[1] Hamadan Univ Med Sci, Sch Pharm, Dept Pharmacol & Toxicol, Hamadan, Hamadan, Iran
[2] Hamadan Univ Med Sci, Sch Pharm, Dept Pharmaceut, Hamadan, Hamadan, Iran
关键词
Silibinin; Nano-silibinin; multiple sclerosis; cuprizonc model; total antioxidant capacity; lipid peroxidation; NANOSTRUCTURED LIPID CARRIER; OXIDATIVE STRESS; SILYBUM-MARIANUM; NANOPARTICLES SLN; FREE-RADICALS; SILYMARIN; ANTIOXIDANT; LIVER; NEUROINFLAMMATION; NEUROTOXICITY;
D O I
10.2174/1574885517666211216161317
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: Multiple sclerosis (MS) is a long-lasting demyelinating inflammatory disease of the central nervous system (CNS). It has been shown that brain tissue in MS is exposed to oxidative stress during the disease period. Silymarin, a plant-derived flavonoid, can be extracted from Silybum marianum. The current experiment aimed to explore the effects of silibinin and especially nano-silibinin on neurobehavioral activity and biochemical antioxidant parameters in the cuprizone model of demyelination in mice for the first time. Methods: Demyelination was induced in mice by oral consumption of cuprizone 0.4%w/w for one week and then 0.2%w/w for four weeks. Treatment was performed with silibinin or nano-silibinin (70mg/kg body weight) for four weeks at the same time with cuprizone 0.2%w/w. After neurobehavioral tests (rotarod, tail flick, and open field), biochemical antioxidant parameters (glutathione level, superoxide dismutase activity, lipid peroxidation products, and total antioxidant capacity) were evaluated. Results: In this experiment, behavioral tests (rotarod and open field) displayed improvement in movement dysfunction using silibinin or nano-silibinin. Furthermore, silibinin and more efficiently nano-silibinin increased antioxidant parameters, such as superoxide dismutase (SOD) and glutathione (GSM and total antioxidant capacity (TAC), and decreased lipid peroxidation. Conclusion: These data suggest that silibinin and nano-silibinin can improve movements in the cuprizone model of demyelination. Moreover, they may prevent cuprizone-induced oxidative stress. In conclusion, silibinin and more effectively, nano-silibinin, may exhibit therapeutic features in MS disease.
引用
收藏
页码:439 / 447
页数:9
相关论文
共 66 条
[1]   Nano-silymarin provides protection against γ-radiation-induced oxidative stress in cultured human embryonic kidney cells [J].
Adhikari, Manish ;
Arora, Rajesh .
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2015, 792 :1-11
[2]   Multiple Sclerosis: Mechanisms and Immunotherapy [J].
Baecher-Allan, Clare ;
Kaskow, Belinda J. ;
Weiner, Howard L. .
NEURON, 2018, 97 (04) :742-768
[3]   Serum levels of antioxidant vitamins and lipid peroxidation in multiple sclerosis [J].
Besler, HT ;
Çomoglu, S ;
Okçu, Z .
NUTRITIONAL NEUROSCIENCE, 2002, 5 (03) :215-220
[4]   Antioxidants in multiple sclerosis - Do they have a role in therapy? [J].
Carlson, Noel G. ;
Rose, John W. .
CNS DRUGS, 2006, 20 (06) :433-441
[5]   Novel Targets in Multiple Sclerosis: To Oxidative Stress and Beyond [J].
Chiurchiu, Valerio .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2014, 14 (22) :2590-2599
[6]   Measuring Motor Coordination in Mice [J].
Deacon, Robert M. J. .
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2013, (75) :e2609
[7]   Immunopathology of multiple sclerosis [J].
Dendrou, Calliope A. ;
Fugger, Lars ;
Friese, Manuel A. .
NATURE REVIEWS IMMUNOLOGY, 2015, 15 (09) :545-558
[8]   Free radicals in the physiological control of cell function [J].
Dröge, W .
PHYSIOLOGICAL REVIEWS, 2002, 82 (01) :47-95
[9]   Lipid nanoparticles as vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC) [J].
Fang, Jia-You ;
Fang, Chia-Lang ;
Liu, Chi-Hsien ;
Su, Yu-Han .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2008, 70 (02) :633-640
[10]   RANDOMIZED CONTROLLED TRIAL OF SILYMARIN TREATMENT IN PATIENTS WITH CIRRHOSIS OF THE LIVER [J].
FERENCI, P ;
DRAGOSICS, B ;
DITTRICH, H ;
FRANK, H ;
BENDA, L ;
LOCHS, H ;
MERYN, S ;
BASE, W ;
SCHNEIDER, B .
JOURNAL OF HEPATOLOGY, 1989, 9 (01) :105-113